Claims
- 1. A method for reducing mammalian serum total cholesterol, LDL cholesterol, apolipoprotein B and triglyceride levels in a mammal, said method comprising:
- ingesting a stabilized rice bran derivative selected from the group consisting of an enzyme treated stabilized rice bran, an insolubilized fraction and mixtures thereof, thereby reducing serum total cholesterol, LDL cholesterol, apoliprotein B and triglyceride levels in said mammal.
- 2. The method according to claim 1, wherein said mammal is a human.
- 3. The method according to claim 2, wherein said mammal is suffering from hyperlipidemia.
- 4. The method according to claim 2, wherein said mammal is suffering from cardiovascular disease.
- 5. The method according to claim 2, wherein said mammal is suffering from atherosclerosis.
- 6. The method according to claim 2, wherein said mammal is suffering from arteriosclerosis.
- 7. The method according to claim 2, wherein said mammal is suffering from xanthomatosis.
- 8. The method according to claim 1, wherein said rice bran derivative is an enzyme treated stabilized rice bran derivative.
- 9. The method according to claim 8, wherein said enzyme treated rice bran derivative comprises about 40% to about 60% total dietary fiber content w/w.
- 10. The method according to claim 1, wherein said rice bran derivative is an insolubilized fraction.
- 11. The method according to claim 10, wherein said rice bran derivative is an insolubilized fraction comprising about 40% to about 60% total dietary fiber content w/w.
- 12. The method according to claim 10, wherein said rice bran derivative is an insolubilized fraction comprising about 1% to about 20% total non-fiber carbohydrate content w/w.
- 13. The method according to claim 10, wherein said rice bran derivative is an insolubilized fraction comprising about 10% to about 20% total fat content w/w.
- 14. The method according to claim 10, wherein said rice bran derivative is an insolubilized fraction comprising about 15% to about 25% total protein content w/w.
- 15. The method according to claim 2, wherein said derivative is ingested in an amount of about 10 grams to about 100 grams per day total.
- 16. The method according to claim 15, wherein said amount is ingested in at least 2 doses.
- 17. The method according to claim 15, wherein said amount is about 10 grams to about 40 grams per day total.
- 18. The method according to claim 15, wherein said amount is about 15 grams to about 30 grams per day total.
- 19. A method for reducing triglyceride levels in mammalian serum in a mammal, said method comprising:
- ingesting a stabilized rice bran derivative selected from the group consisting of an enzyme treated stabilized rice bran derivative, an insolubilized fraction and mixtures thereof, thereby reducing said triglyceride levels in said mammalian serum.
- 20. The method according to claim 19, wherein said mammal is a human.
- 21. The method according to claim 19, wherein said rice bran derivative is an enzyme treated stabilized rice bran derivative.
- 22. The method according to claim 19, wherein said rice bran derivative is an insolubilized fraction.
- 23. A method for reducing apolipoprotein B levels in mammalian serum in a mammal, said method comprising:
- ingesting a stabilized rice bran derivative selected from the group consisting of an enzyme treated stabilized rice bran derivative, an insolubilized fraction and mixtures thereof, thereby reducing said apolipoprotein B levels in said mammalian serum.
- 24. The method according to claim 23, wherein said mammal is a human.
- 25. The method according to claim 23, wherein said rice bran derivative is an enzyme treated stabilized rice bran derivative.
- 26. The method according to claim 23, wherein said rice bran derivative is an insolubilized fraction.
RELATED APPLICATIONS
The present application claims the benefit of U.S. patent application Ser. No. 60/057,870, filed Sep. 2, 1997, the teachings of which are incorporated herein by reference.
US Referenced Citations (11)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 457 539 B1 |
Jan 1994 |
EPX |